TCGA-86-8073-01A-11R-2241-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 58
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.430
- UV_RESPONSE_DN+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
- ANDROGEN_RESPONSE+0.220
- PEROXISOME+0.200
- MITOTIC_SPINDLE+0.190
- TGF_BETA_SIGNALING+0.170
- CHOLESTEROL_HOMEOSTASIS+0.140
- NOTCH_SIGNALING+0.140
- BILE_ACID_METABOLISM+0.130
Top 10 suppressed
- E2F_TARGETS-0.440
- PANCREAS_BETA_CELLS-0.370
- G2M_CHECKPOINT-0.360
- MYC_TARGETS_V2-0.360
- TNFA_SIGNALING_VIA_NFKB-0.340
- MYC_TARGETS_V1-0.330
- APICAL_SURFACE-0.310
- INFLAMMATORY_RESPONSE-0.270
- OXIDATIVE_PHOSPHORYLATION-0.260
- HYPOXIA-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-8087-01A-11R-2241-07 | — | cohortA1 | 0.799 |
| 2 | SRR1404601 | GTEX | — | 0.799 |
| 3 | SJEPD030486_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.794 |
| 4 | TCGA-E2-A15P-01A-11R-A115-07 | — | B | 0.793 |
| 5 | MNG526 | — | — | 0.786 |
| 6 | f7683b51.cca9.4079.9e34.b9a4fdd27d85 | — | cohortA1 | 0.781 |
| 7 | TCGA-A7-A0DB-01A-11R-A277-07 | — | D | 0.770 |
| 8 | TCGA-A7-A26E-01A-11R-A169-07 | — | B | 0.768 |
| 9 | TCGA-44-6146-01A-11R-A278-07 | — | cohortA1 | 0.765 |
| 10 | MNG1049 | — | — | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |